ALL
Pharma?in?China
Pharma?Experts
Market News
Products Guide
Brand Story
-
Liminal BioSciences Resubmits BLA for Ryplazim for Congenital Plasminogen Deficiency americanpharmaceuticalreview
September 17, 2020Liminal BioSciences announced the Company, through its U.S. subsidiary Prometic Biotherapeutics Inc., has filed a resubmission of the Biologics License Application (BLA) for Ryplazim? (plasminogen) (Ryplazim?) with the U.S. Food and Drug Administration...
Pharma Sources Insight January 2025
